Ettinger DS, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer, Version 3.2019. National Comprehensive Cancer Network. 2019 January 18.
Care Coordination Clinical Practice Guidelines
Hanna N, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guidelhttps://onlinelibrary.wiley.com/doi/full/10.3322/caac.21446ine Update. J Clin Oncol.2017 Oct 20;35930):3484-3515.
Smith RA, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA cancer J Clin. 2018 Jul;68(4):297-316.
Brody R, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;Oct;112:200-215.
Esposito AR, et al. The role of circulating free DNA in the management of NSCLC. Expert Rev Anticancer Ther. 2018 Nov 21:1-10
Goodman AM, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017; Nov;16(11):2598-2608.
Thakur MK, et al. Predictive and prognostic biomarkers in non-small cell lung cancer. Semin Respir Crit Care Med. 2016;Oct;37(5):760-770.
Bilfinger TV, et al. Survival outcomes among lung cancer patients treated using a multidisciplinary team. Clin Lung Cancer. 2018;19(4):346-351.
Smeltzer MP, et al. Pragmatic trial of a multidisciplinary lung cancer care model in a community healthcare setting: study design, implementation evaluation, and baseline clinical results. Transl Lung Cancer Res. 2018 Feb; 7(1):88-102.
Below are resources that include process improvement opportunities, case studies of effective practices, webinars, and practical tools developed by ACCC:
This project is made possible by support from AstraZeneca.